Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 7/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921665 | 0.90 | PTGES (0.38) | TP53POLBPTGESPKM | |
| SCHEMBL4924523 | 0.79 | SMN1; SMN2 (0.43) | MAPTGAATP53SMN1; SMN2THRB | |
| SCHEMBL3013050 | 0.76 | MAPT (0.49) | MAPTGAATP53POLBSMN1; SMN2 | |
| SCHEMBL3011861 | 0.76 | MEN1 (0.51) | MAPTGAATP53POLBSMN1; SMN2 | |
| SCHEMBL3577781 | 0.76 | SMN1; SMN2 (0.42) | MAPTGAATP53POLBSMN1; SMN2 | |
| SCHEMBL3571150 | 0.76 | MAPT (0.45) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL4914794 | 0.75 | PTGES (0.46) | TP53POLBSMN1; SMN2THRBPTGES | |
| SCHEMBL4924856 | 0.75 | PTGES (0.39) | TP53POLBPTGESPKM | |
| SCHEMBL4918381 | 0.74 | MAPT (0.46) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL3573520 | 0.74 | SMN1; SMN2 (0.43) | MAPTTP53POLBSMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | MAPT 89/4885GAA 4093/4885TP53 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.